Advertisement

Topics

Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan

07:17 EDT 17 May 2019 | Generics and Biosimilars Initiative

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 9 April 2019 that they had made a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar, Stelara, in Japan.

Original Article: Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan

NEXT ARTICLE

More From BioPortfolio on "Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...